• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

XRCC1 Gene Record

  • Summary
  • Interactions
  • Claims
  • XRCC1 7515

    Alternate Names:

    7515
    X-RAY REPAIR CROSS COMPLEMENTING 1
    XRCC1
    RCC
    SCAR26
    194360
    12828
    ENSG00000073050
    OTTHUMG00000182699
    6144
    PA369

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (1 More Sources)

    Gene Categories: Category Details

    Publications:

    Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer
    Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
    Misra et al., 2003, Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland., Cancer Lett.
    Marsh et al., 2007, Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer., J. Clin. Oncol.
    Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
    Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
    Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
  • VITAMIN E   XRCC1

    Interaction Score: 1.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12618330


    Sources:
    NCI

  • PLATINUM   XRCC1

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17925548


    Sources:
    NCI

  • VINORELBINE   XRCC1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19157633


    Sources:
    CIViC

  • CYCLOPHOSPHAMIDE   XRCC1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22188361 19786980


    Sources:
    PharmGKB

  • DOCETAXEL   XRCC1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19157633


    Sources:
    CIViC

  • CARBOPLATIN   XRCC1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16875718


    Sources:
    CIViC

  • GEMCITABINE   XRCC1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19157633


    Sources:
    CIViC

  • FLUOROURACIL   XRCC1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23314736


    Sources:
    PharmGKB

  • CISPLATIN   XRCC1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16875718


    Sources:
    CIViC

  • DOXORUBICIN   XRCC1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000073050

    • Version: 101_38

    Alternate Names:
    XRCC1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: XRCC1

    • Version: 18-August-2020

    Alternate Names:
    PA369 PharmGKB ID

    Gene Info:

    Publications:
    Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
    Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
    Shahnam A et al., 2016, Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis., Pharmacogenomics

  • CIViC: XRCC1

    • Version: 14-September-2020

    Alternate Names:
    7515 Entrez Gene ID
    6144 CIViC Gene ID

    Gene Info:

    Publications:
    Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
    Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer

  • NCI: XRCC1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Misra et al., 2003, Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland., Cancer Lett.
    Marsh et al., 2007, Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer., J. Clin. Oncol.
    Andersson et al., 1996, Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs., Cancer Chemother. Pharmacol.

  • Tempus: XRCC1

    • Version: 11-November-2018

    Alternate Names:
    XRCC1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21